ARA-290 (Cibinetide) – Comprehensive Research Overview (2026)

ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, ARA-290 selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the β-common receptor (βcR) — without stimulating erythropoiesis or thrombosis. ARA-290 is primarily researched for neuropathic pain, small fiber neuropathy, sarcoidosis, and metabolic disorders. It has received Orphan Drug Designation from the FDA and EMA for sarcoidosis-associated small fiber neuropathy.

→ View ARA-290 (for laboratory research use only)

Mechanism of Action

  • Selectively activates the innate repair receptor (IRR / EPO-R + βcR heterodimer).
  • Promotes neuronal survival, repair, and regeneration without erythropoietic effects.
  • Reduces neuroinflammation via suppression of TNF-α, IL-6, and NF-κB pathways.
  • Improves small fiber nerve density and function in neuropathy models.
  • Metabolic effects: improves insulin sensitivity and reduces inflammatory cytokines in metabolic disease models.

Clinical Evidence and Research Findings

Phase 2 trials in sarcoidosis-associated small fiber neuropathy demonstrated significant improvements in neuropathic pain, corneal nerve fiber density, and quality of life. Metabolic studies show improvements in HbA1c and insulin sensitivity in T2D patients. FDA and EMA Orphan Drug Designation for sarcoidosis. Phase 3 trials are ongoing.

→ Interested in researching ARA-290? View Product Options

Benefits (Research & Clinical Observations)

  • Neuropathic pain reduction
  • Small fiber nerve regeneration and density improvement
  • Anti-inflammatory effects without immunosuppression
  • Metabolic improvements (insulin sensitivity, HbA1c)
  • FDA/EMA Orphan Drug Designation for sarcoidosis

Typical Dosing Protocols (Clinical Trials)

  • Clinical trial doses: 4 mg subcutaneous daily for 28 days (sarcoidosis trials)
  • Off-label research protocols vary; typically 1–4 mg subcutaneous daily

Safety Profile and Side Effects

ARA-290 has an excellent safety profile in clinical trials with no erythropoietic or thrombotic effects. Common side effects: mild injection-site reactions. No significant adverse events reported at clinical doses.

Summary

ARA-290 (Cibinetide) is a tissue-protective EPO analog with Orphan Drug Designation and compelling Phase 2 evidence for neuropathic pain, small fiber neuropathy, and metabolic improvement. Its selective IRR activation without erythropoietic effects makes it a uniquely safe neuroprotective research tool. As with all compounds in this library, ARA-290 is not yet an approved drug and should only be considered under qualified medical supervision.

For Laboratory Research Use View ARA-290 →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.